Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Andrew Huberman: Oh, so it's really competitive
Weight gain: Higher risk of gaining weight, especially around the abdomen, which continues after menopause
It supports healing from ulcers, leaky gut syndrome, IBS, and other inflammatory bowel issues
Novo Nordisk and the Next Wave of Weight Loss Drugs The Two-Company Market: Q1 2026 Head to Head Key Numbers Total Revenue: $19.8B (+56% YoY) Adjusted EPS: $8.55 (+156%) Mounjaro: $8.66B (+100%+ YoY) Zepbound: $4.16B (+80% YoY) US Market Share: 60.1% 2026 Guide: $82-85B (raised $2B) Total Revenue: $10.8B (beat estimates) Adjusted EPS: $1.03 (beat) Wegovy: DKK 18.2B (+12% YoY) Wegovy Pill: $354M (doubled estimates) US Market Share: 39.4% 2026 Guide: Adjusted sales decline 4-12% at CER The GLP-1 market in 2026 is a two-company duopoly with a widening gap
%20(1).png)
/assets/production/practices/f83709c32c8bb4394de92636b30179c2a6dd62a3/images/2845033.png)
